Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/an-exploratory-analysis-of-proprotein-convertase-subtilisin-kexin-type-gFnY7MCMmx
References (16)
-
A. Langsted, B. Nordestgaard, M. Benn, A. Tybjærg‐Hansen, P. Kamstrup (2016)
PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.The Journal of clinical endocrinology and metabolism, 101 9
-
Arsenault (2014)
Lipoprotein(a) levels, genotype, and incident aortic valve stenosis.Circ Cardiovasc Genet, 7
-
K. Zheng, S. Tsimikas, T. Pawade, J. Kroon, W. Jenkins, M. Doris, A. White, N. Timmers, J. Hjortnaes, M. Rogers, E. Aikawa, B. Arsenault, J. Witztum, D. Newby, M. Koschinsky, Z. Fayad, E. Stroes, S. Boekholdt, M. Dweck (2019)
Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic StenosisJournal of the American College of Cardiology, 73
-
M. Sabatine, R. Giugliano, A. Keech, Narimon Honarpour, Huei Wang, Thomas Liu, S. Wasserman, R. Scott, P. Sever, T. Pedersen (2016)
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.American heart journal, 173
-
V. Bittner, M. Szarek, P. Aylward, Deepak Bhatt, R. Diaz, J. Edelberg, Z. Fras, S. Goodman, S. Halvorsen, C. Hanotin, R. Harrington, J. Jukema, V. Loizeau, P. Moriarty, A. Moryusef, R. Pordy, M. Roe, P. Sinnaeve, S. Tsimikas, R. Vogel, H. White, D. Zahger, A. Zeiher, P. Steg, G. Schwartz (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.Journal of the American College of Cardiology, 75 2
-
M. Sabatine, R. Giugliano, A. Keech, Narimon Honarpour, S. Wiviott, S. Murphy, J. Kuder, Huei Wang, Thomas Liu, S. Wasserman, P. Sever, T. Pedersen (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseThe New England Journal of Medicine, 376
-
Y. Bossé, P. Mathieu, P. Pibarot (2008)
Genomics: the next step to elucidate the etiology of calcific aortic valve stenosis.Journal of the American College of Cardiology, 51 14
-
M. O’Donoghue, S. Fazio, R. Giugliano, Erik Stroes, Estella Kanevsky, I. Gouni-Berthold, K. Im, Armando Pineda, S. Wasserman, R. Češka, M. Ezhov, J. Jukema, Henrik Jensen, S. Tokgözoğlu, F. Mach, K. Huber, P. Sever, A. Keech, T. Pedersen, M. Sabatine (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER TrialCirculation, 139
-
B. Stewart, D. Siscovick, Bonnie Lind, J. Gardin, J. Gottdiener, V. Smith, D. Kitzman, C. Otto (1997)
Clinical Factors Associated With Calcific Aortic Valve DiseaseJournal of the American College of Cardiology, 29
-
L. Mundal, A. Hovland, J. Igland, M. Veierød, K. Holven, M. Bogsrud, G. Tell, T. Leren, K. Retterstøl (2019)
Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia.JAMA cardiology
-
G. Thanassoulis, Catherine Campbell, D. Owens, J. Smith, Albert Smith, G. Peloso, K. Kerr, S. Pechlivanis, M. Budoff, T. Harris, R. Malhotra, K. O’Brien, P. Kamstrup, B. Nordestgaard, A. Tybjaerg-hansen, M. Allison, T. Aspelund, M. Criqui, S. Heckbert, Shih-Jen Hwang, Yongmei Liu, M. Sjőgren, Jesper Pals, H. Kälsch, Thomas Mühleisen, M. Nöthen, L. Cupples, M. Caslake, E. Angelantonio, J. Danesh, J. Rotter, S. Sigurdsson, Q. Wong, R. Erbel, S. Kathiresan, O. Melander, V. Gudnason, Christopher O’Donnell, W. Post (2013)
Genetic associations with valvular calcification and aortic stenosis.The New England journal of medicine, 368 6
-
K. Chan, K. Teo, Jean Dumesnil, A. Ni, J. Tam (2010)
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) TrialCirculation, 121
-
S. Cowell, D. Newby, R. Prescott, P. Bloomfield, J. Reid, D. Northridge, N. Boon (2005)
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.The New England journal of medicine, 352 23
-
R. Capoulade, K. Chan, C. Yeang, P. Mathieu, Y. Bossé, J. Dumesnil, J. Tam, K. Teo, A. Mahmut, Xiaohong Yang, J. Witztum, B. Arsenault, J. Despres, P. Pibarot, S. Tsimikas (2017)
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calci fi c Aortic Valve Stenosis -
Benoit Arsenault, S. Boekholdt, M. Dubé, É. Rhéaume, M. Sandhu, N. Wareham, K. Khaw, J. Tardif (2013)
Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohortEuropean Heart Journal, 34
-
A. Rossebø, T. Pedersen, K. Boman, P. Brudi, J. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Bärwolf, I. Holme, Y. Kesäniemi, W. Malbecq, C. Nienaber, S. Ray, T. Skjærpe, K. Wachtell, R. Willenheimer (2008)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.The New England journal of medicine, 359 13
- Publisher
- American Medical Association
- Copyright
- Copyright 2020 American Medical Association. All Rights Reserved.
- ISSN
- 2380-6583
- eISSN
- 2380-6591
- DOI
- 10.1001/jamacardio.2020.0728
- Publisher site
- See Article on Publisher Site
Abstract
Key PointsQuestionWhat is the association between lipoprotein(a) and low-density lipoprotein–cholesterol concentrations and aortic stenosis events, and does proprotein convertase subtilisin/kexin type 9 inhibition reduce the risk of aortic stenosis events? FindingsIn this secondary analysis of 63 patients in a randomized clinical trial, elevated lipoprotein(a) concentrations were associated with higher rates of aortic stenosis events, including aortic valve replacement. The overall hazard ratio for aortic stenosis events with evolocumab was 0.66 (95% CI, 0.40-1.09), with no apparent association in the first year (hazard ratio, 1.09 [95% CI, 0.48-2.47]) but a hazard ratio of 0.48 (95% CI, 0.25-0.93) after the first year of treatment. MeaningLong-term therapy with evolocumab may reduce the risk of aortic stenosis events, although these findings require validation in a dedicated randomized clinical trial.
Journal
JAMA Cardiology – American Medical Association
Published: Jun 29, 2020